Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Q1FY23 Quarterly Result Announced for Alembic Pharmaceuticals Ltd.

 Alembic Pharmaceuticals announced Q1FY23 results: Alembic reports revenue for Q1 FY23 Rs. 1262 crore India Branded Business Ex of Covid-related products grew by an impressive 20%. International Generics Business de-grew by 3% to Rs. 549 crore Profit before tax for the quarter is Rs. 47 crore Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said "India Branded Business continues to deliver robust numbers in Q1. India Business will witness market outperforming growth across most of the products and therapy areas in current year." Result PDF
04-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Outcome for Outcome Of Board Meeting

 With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved: 1) Unaudited Financial Results for the quarter ended 30th June, 2022. 2) Re-classification of the dividend of Rs. 10/- (500%) per equity share for the financial year 2021-22, recommended by them at their meeting held on 2nd May, 2022, into interim dividend for the financial year 2021-22. Please note that the said interim dividend will be paid to those shareholders whose names appear on the Register of Members as on the Record Date fixed for the purpose i.e. Thursday, 18th August, 2022. No further final dividend for the financial year 2021-22 shall be declared. The time of commencement of the Board Meeting was 12:30 p.m. and the time of conclusion was 3:30 p.m. We request you to kindly take the same on record.
04-08-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Revision in timings of Post Results Conference Call The exchange is hereby informed that the Company's Post Results Conference Call will be held on 4th August, 2022 at 4:15 p.m., as per the revised details enclosed. We request you to kindly take the same on record.
02-08-2022

Alembic Pharma receive USFDA approval to market drug for skin treatment

 Alembic Pharmaceuticals on Friday said its subsidiary has received approval from the US health regulator to market medication for treating actinic keratoses
29-07-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company's wholly owned subsidiary, Aleor Dermaceuticals Limited has received US Food and Drug Administration (USFDA) Final Approval for Diclofenac Sodium Topical Gel, 3%. Please find enclosed herewith our press release. We request you to kindly take the same on record.
29-07-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 of the Listing Regulations, 2015, we enclose herewith a copy of the notice published in Economic Times (English edition), Indian Express (English edition) and Financial Express (Gujarati edition - vernacular language) on 28th July, 2022 informing about the Record Date fixed to determine the list of shareholders entitled to receive Interim Dividend for the financial year 2021-22, if declared by the Board of Directors at their meeting scheduled to be held on 4th August, 2022. We request you to kindly take the same on record.
28-07-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 The exchange is hereby informed that the Company will hold Post Results Conference Call on 4th August, 2022 as per the enclosed details. We request you to kindly take the same on record.
27-07-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Intimation Of Record Date For Payment Of Interim Dividend On Equity Shares For The Financial Year 2021-22

 Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has fixed Thursday, 18th August, 2022 as the Record Date to determine the list of shareholders entitled to receive Interim Dividend for the financial year 2021-22, if declared by the Board of Directors at their meeting scheduled to be held on 4th August, 2022. We request you to kindly take the same on your record and display the same on the website of the Stock Exchange.
27-07-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Update on board meeting

 ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2022 ,inter alia, to consider and approve With reference to the captioned matter and in continuation to the above referred intimation, the exchange is hereby informed that the Board of Directors of the Company at their meeting scheduled to be held on 4th August, 2022 shall also consider and approve re-classification of the final dividend of Rs. 10/- (500%) per equity share for the financial year 2021-22, recommended by them at their meeting held on 2nd May, 2022, into interim dividend for the financial year 2021-22. We request you to kindly take the same on record.
27-07-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificate(s) published by the Company on behalf of the registered shareholder(s) and/or their legal heir(s) in Business Standard (English edition) on 21st July, 2022. We request you to kindly take the same on record.
21-07-2022
Next Page
Close

Let's Open Free Demat Account